Press & Statements

CSRxP APPLAUDS REINTRODUCTION OF REMEDY ACT IN U.S. SENATE 

Jul 31, 2024

Bipartisan, Market-Based Solution Would Help Crack Down on Anti-Competitive Read More

CSRXP: BIG PHARMA IS AT IT AGAIN, HIKES PRICES ON NEARLY 200 PRESCRIPTION DRUGS AS PART OF MID-YEAR INCREASES

Jul 15, 2024

Brand Name Drug Giants’ Average Price Increases for June-July Outpace Rate Read More

CSRXP APPLAUDS U.S. SENATE PASSAGE OF BIPARTISAN, MARKET-BASED SOLUTION TO CRACK DOWN ON BIG PHARMA’S PATENT THICKETS

Jul 11, 2024

Legislation Would Hold Big Pharma Accountable for Anti-Competitive Tactics Read More

NEW GOODRX REPORT UNDERSCORES NEED FOR CONGRESS TO HOLD BIG PHARMA ACCOUNTABLE

Jul 2, 2024

Latest Data Finds List Prices of Prescription Drug Prices Have Increased Read More

CSRXP APPLAUDS EXPANDED FTC CRACK DOWN ON BIG PHARMA’S SHAM PATENTS IN THE ORANGE BOOK

Apr 30, 2024

Commission Builds on Previous Action by Targeting More Than 300 Patents, Read More

CSRXP COMMENDS PRESIDENT BIDEN FOR HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE AND EGREGIOUS PRICING ON BRAND NAME INHALERS

Apr 3, 2024

President Says ‘Drug Companies Are Charging Exorbitant Prices’ in Press Read More

Advisory: Panel Discussion on Big Pharma’s Patent Abuse with CSRxP Executive Director Lauren Aronson

Feb 6, 2024

Lawmakers and Experts Will Discuss Solutions to Hold Big Pharma Accountable Read More

CSRXP: GSK’S FLOVENT SCHEME DESIGNED TO SIDESTEP ACCOUNTABILITY FOR EGREGIOUS PRICE HIKES

Jan 5, 2024

Big Pharma Giant Switches Popular Brand Name Inhaler to Authorized Generic to Read More

CSRXP: BIG PHARMA RINGS IN 2024 WITH EGREGIOUS PRICE HIKES ON HUNDREDS OF BRAND NAME PRESCRIPTION DRUGS

Jan 2, 2024

Big Pharma Maintains Business-as-Usual Approach to Price-Gouging Americans to Read More

CSRXP: BIG PHARMA DOUBLES DOWN ON EGREGIOUS PRICE HIKES OUTPACING INFLATION

Dec 14, 2023

Administration Announces Drug Makers Increased Prices Faster Than Rate of Read More